carboplatin and etoposide

DRUG4 trials

Sponsors

ImmunoGen, Inc., Cephalon, Shanghai Henlius Biotech

Conditions

Extensive Stage Small Cell Lung CancerExtensive-stage Small Cell Lung CancerSmall Cell Lung CancerSmall-cell Lung Cancer

Phase 1

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

TerminatedNCT01237678

ImmunoGen, Inc.Small Cell Lung Cancer

Start: 2010-11-30End: 2015-05-31Updated: 2018-01-18

Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Shanghai Henlius BiotechSmall-cell Lung Cancer

Start: 2023-03-29End: 2024-05-29Target: 20Updated: 2022-05-04

Phase 3

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

WithdrawnNCT01563601

CephalonExtensive-stage Small Cell Lung Cancer

Start: 2012-08-31End: 2018-01-31Updated: 2012-08-15

A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC

CompletedNCT04063163

Shanghai Henlius BiotechExtensive Stage Small Cell Lung Cancer

Start: 2019-09-12End: 2024-05-07Updated: 2025-12-09

Related Papers

Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients

Clinical and Translational Science2025-09-01

Serplulimab versus placebo plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study.

Journal of Clinical Oncology2025-05-28

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.

Journal of Clinical Oncology2024-06-014 citations

Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.

Journal of Clinical Oncology2024-06-01

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

Frontiers in Immunology2023-01-0440 citations

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

JAMA2022-09-27413 citations

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Journal of Clinical Oncology2022-06-0135 citations

Antibodies to watch in 2020.

2020-01-01328 citations